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Introduction: CD14 is one of the leukocyte differentiation antigens, and is present in macro-
phages, monocytes, granulocytes and their cell membranes. Presepsin, namely soluble
CD14-subtype (sCD14-ST) is produced by circulating plasma proteases activating cleavage of
soluble CD14 (sCD14). The aim of this study is to investigate the role of Presepsin and the
CURB65 scoring system in the evaluation of severity and outcome of CAP in an ED.
Method: A prospective, observational study was performed in an ED of an university teaching
hospital from November 2011 to October 2012. A total of 359 patients with CAP and 214 pa-
tients with severe CAP (SCAP) were consecutively enrolled. Plasma Presepsin, lactate, serum
PCT levels and leukocyte counts were measured and CURB65 score were calculated at admis-
sion enrollment.
Result: Plasma Presepsin levels were significantly higher in SCAP patients than in CAP patients
(P < 0.0001), increasing correspondingly with the enhancement of CURB65 score. Patients with
ARDS or DIC had obviously higher plasma Presepsin levels than those without ARDS or DIC (all
P < 0.0001), and plasma Presepsin levels were significantly higher in non-survivors than in sur-
vivors at 28-day follow-up. In logistic regression analysis, CURB65 score was the independent
predictor of ARDS, and Presepsin was the independent predictor of DIC, and Presepsin and
CURB65 score were both the independent predictors of 28-day mortality. The AUCs showed
Presepsin in combination with CURB65 score in predicting ARDS, SCAP and 28-day mortalitytment; CAP, community-acquired pneumonia; SCAP, severe CAP; DIC, disseminated intravascular
DS, acute respiratory distress syndrome; PCT, procalcitonin; PSI, pneumonia severity index; CURB65
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Role of Presepsin (sCD14-ST) and the CURB65 scoring system 1205was superior to Presepsin or CURB65 score alone ( all P < 0.01), Presepsin was better than
CURB65 score and leukocyte in predicting DIC ( P < 0.01).
Conclusion: Presepsin is a valuable biomarker in predicting severity and outcome in CAP pa-
tients in the ED and Presepsin in combination with CURB65 score significantly enhanced the
predictive accuracy.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) is a common and
potentially serious illness, and is considered to be the
leading cause of deaths associated with infectious disease
in developed countries [1]. Accurate, objective, and early
disease severity assessment and prediction of outcome in
patients with CAP are crucial for optimized management
decisions regarding care setting, extent of assessment, and
level of treatment.
Scoring systems have been used to evaluate the severity
or outcome of CAP in recent years. At present, the Pneu-
monia Severity Index (PSI) and CURB65 have been the most
widely used scoring systems. PSI is comprised of a 20-point
score that classifies patients into five risk categories based
on their risk of death within 30 days. This score was
developed to identify patients at low risk of death, who
could be recommended for outpatient treatment [2].
However, PSI is limited by the number of included vari-
ables, making it complex to use in a busy emergency
department (ED) setting [3]. The CURB65 score consists of
five predictors, including confusion, urea >7 mmol/L, res-
piratory rate 30 breaths per minute, systolic pressure
<90 mm Hg or diastolic pressure 60 mm Hg, and age
65 years [4], and is significantly easier to use than PSI as a
single point is awarded to each variable and is more easily
applied in an ED setting. In addition, although CURB65
consists of a simple 5-point score, a comparison found no
significant differences between PSI and CURB65 in pre-
dicting mortality in CAP patients [5]. Scoring systems are
useful for optimizing and reducing unnecessary hospital
admission rates, but they do not reflect aspects of the
pathophysiology of disease. Thus, additional risk factors
and prognostic biomarkers could potentially enhance the
prognostic performance of these established risk scores in
CAP patients.
CD14 is one of the leukocyte differentiation antigens,
and is present in macrophages, monocytes, and gran-
ulocytes and their cell membranes. CD14 exists in two
forms, membrane CD14 (mCD14) and soluble CD14 (sCD14)
[6,7]. CD14 is a pattern recognition receptor for several
conserved bacterial motifs, including lipopolysaccharide,
the toxic moiety in the outer membrane of Gram-negative
bacteria, and peptidoglycan and lipoteichoic acid, both
major components of the Gram-positive bacteria cell wall
[7e9]. Soluble CD14-subtype (sCD14-ST), or Presepsin, is
produced by circulating plasma proteases activating
cleavage of sCD14 [10], which is a new biomarker of sepsis.
Previous clinical studies have confirmed that Presepsin
levels increased in sepsis and with severity of disease[11e13]. However, the correlation between Presepsin and
CAP, one of the most common causes of sepsis, with high
morbidity and mortality, has not yet been determined.
Therefore, the aim of this study was to investigate the role
of Presepsin and the CURB65 score in the assessment of
severity, adverse medical events and 28-day mortality in
CAP patients in an ED.
Materials and methods
Study institution and subjects
This prospective, observational study was conducted in the
ED of Beijing Chao-Yang Hospital, an university teaching
hospital with approximately 240,000e260,000 ED admis-
sions per year. From November 2011 to October 2012,
consecutive patients suspected of CAP at ED admission
were enrolled.
Exclusion criteria were as follows: age less than
18 years; terminal stage of disease (malignant cancer of any
type, end-stage liver, or renal disease); hospitalized within
14 days before the onset of symptoms; cystic fibrosis;
active pulmonary tuberculosis; severe immunosuppression;
coagulopathy; systemic anticoagulant treatment; pre-
treatment outside hospital; and the patient or relatives did
not consent to participate in the study. This study was
approved by the Institutional Review Board of Beijing Chao-
Yang Hospital and written informed consent forms were
obtained from all participants.
At enrollment, subject data, including name, age, sex,
past medical history, and vital signs, were recorded. Lab-
oratory examinations, including whole blood leukocyte
count, blood gas analysis, blood biochemistry, and X-rays,
were recorded within 24 h. The CURB65 scores were
calculated on the basis of vital signs and laboratory findings
[4].
Definition of CAP and SCAP, ARDS, and DIC
CAP was defined as the presence of a new infiltrate on a
chest radiograph and at least one of the following signs and
symptoms: cough, sputum production, dyspnea, core body
temperature >38.0 C, auscultatory findings of abnormal
breath sounds, and rales [14]. Severe CAP (SCAP) was
defined as having one of two major criteria (the need for
invasive mechanical ventilation or vasopressors) or three of
nine minor criteria (respiratory rate 30 breaths/min,
PaO2/FiO2 250 mm Hg, multilobar infiltrates, confusion,
serum urea nitrogen level 20 mg/dL, white blood cell
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mm3, core temperature <36 C, and hypotension requiring
aggressive fluid resuscitation) [1]. CAP was confirmed by an
independent radiologist at admission to the ED.
According to the American-European Consensus Confer-
ence on Acute Respiratory Distress Syndrome (ARDS), the
diagnostic criteria of ARDS are as follows: acute-onset
symptoms, PaO2/FiO2 <200 mm Hg, bilateral infiltrates on
chest radiography, and no clinical evidence of left atrial
hypertension [15]. According to the criteria of the Inter-
national Society on Thrombosis and Haemostasis subcom-
mittee, disseminated intravascular coagulation (DIC) score
is determined from platelet count, prothrombin time,
fibrinogen, and fibrin degradation products; a score 5 is
considered overt DIC and a lower score is considered non-
DIC [16]. ARDS or DIC was diagnosed by two experienced
physicians who did not participate in this study.
Measurement of Presepsin and other laboratory
parameters
Venous blood samples were obtained at ED admission and
collected in tubes containing heparin or ethylenediamine-
tetraacetate, and preserved by freezing at 80 C after
collection for analysis within 24 h. Plasma Presepsin con-
centrations were determined using a compact automated
immunoanalyzer (PATHFAST; Mitsubishi Chemical Medience
Corporation, Tokyo, Japan) based on a chemiluminescentTable 1 Baseline patient characteristics at enrollment.
Characteristics CAP
(n Z 359)
Patient demographics
Age (years) 71 (59e78)
Male sex, n (%) 221 (61.6%)
ICU admission 33 (9.2%)
Ward admission 114 (31.8%)
Outcome
DIC, n (%) 39 (10.9%)
ARDS, n (%) 0 (0)
28-day mortality, n (%) 79 (22%)
Co-morbidities
Hypertension 215 (59.9%)
Diabetes mellitus 163 (45.4%)
Chronic heart failure 168 (46.8%)
COPD 125 (34.8%)
Cerebrovascular disease 68 (18.9%)
Chronic renal dysfunction 88 (24.5%)
Neoplastic disease 35 (9.7%)
Laboratory parameters
Presepsin (pg/mL) 400.0 (231.5e691.5
Lactate (mmol/L) 2.2 (1.7e2.5)
PCT (ng/mL) 0.29 (0.05e1.5)
Leukocyte count (  109/L) 10.83 (7.61e14.87)
Risk assessment
CURB65 score 2 (1e3)
CURB score 1 (1e2)
CAP: community-acquired pneumonia; SCAP: severe CAP; DIC: dissem
syndrome; COPD: chronic obstructive pulmonary diseases; PCT: proc
30 breaths per minute, systolic pressure <90 mm Hg or diastolic prenzyme immunoassay, and assay results were obtained
within 17 min. This assay has a normal reference range of
60e365 pg/mL.
Serum procalcitonin (PCT) levels were measured by
BioMerieux Mini VIDAS immunoassay analyzer (Block Scien-
tific, Bohemia, NY, USA). A PCT level <0.05 ng/mL was
regarded as normal. Plasma lactate levels were measured
by blood gas analyzer (GEM Premier 3000, Instrumentation
Laboratory, Lexington, MA, USA). The normal range was
0.7e2.5 mmol/L.
Outcome
For outcome assessment, a follow-up examination was
planned at the 28th day after inclusion in the study. Patients
who survived until follow-up were counted as survivors,
whereas patients who died within the follow-up period were
counted as non-survivors. Adverse medical outcome for this
study was defined as the presence of ARDS, DIC, and death
from any cause at the 28-day follow-up.
Statistical analysis
All data were analyzed by SPSS 16.0 software (SPSS Inc.,
Chicago, IL, USA). Normally distributed data were
expressed as mean  standard derivation, and data with a
skewed distributed as median (25e75th percentile). For
multi-group comparisons, KruskaleWallis one-way analysisSCAP
(n Z 214)
P-value
75 (69e80) <0.001
135 (63.1%) 0.716
104 (48.6%) <0.001
79 (36.9%) 0.206
50 (23.4%) <0.001
125 (58.4%) <0.001
117 (54.7%) <0.001
121 (56.5%) 0.688
101 (47.2%) 0.547
87 (40.7%) 0.635
75 (35.0%) 0.672
29 (13.6%) 0.258
52 (24.3%) 0.266
20 (9.3%) 0.811
) 689.0 (395.5e1225.5) <0.001
2.9 (2.2e6.4) <0.001
1.28 (0.25e8.98) <0.001
12.76 (8.59e18.42) 0.003
4 (3e4) <0.001
3 (2e3) <0.001
inated intravascular coagulation; ARDS: acute respiratory distress
alcitonin; CURB65: confusion, urea >7 mmol/L, respiratory rate
essure 60 mm Hg, and age 65 years.
Figure 1 Comparison of plasma Presepsin levels in patients
with CAP and SCAP, survivors and non-survivors at the 28-day
follow-up between two groups. Lines denote median values,
boxes represent 25e75th percentiles and whiskers indicate the
range.
Figure 2 Comparison of plasma Presepsin levels according to
three CURB65 score categories. Lines denote median values,
boxes represent 25e75th percentiles, and whiskers indicate
the range. CURB65 Z confusion, urea >7 mmol/L, respiratory
rate 30 breaths per minute, systolic pressure <90 mm Hg or
diastolic pressure 60 mm Hg, and age 65 years.
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performed nonparametrically using the ManneWhitney U
test. To compare the predictive value of Presepsin, PCT,
leukocyte, lactate, and CURB65 score on ARDS, DIC, and 28-
day mortality, receiver operating characteristic (ROC)
curves were constructed and the areas under the ROC
curves (AUC) were determined. On the basis of optimal
thresholds determined according to ROC curve analysis,
prognostic parameters (sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV),
positive likelihood ratio (LRþ), and negative likelihood
ratio (LR)) were also calculated. For comparisons of AUCs,
the Z test formula ZZðA1  A2Þ=ðSE21 þ SE22  rSE1SE2Þ1=2
was applied, and the test standard was Z0.05 Z 1.96,
Z0.01Z 2.58. Binary logistic regression analysis was applied
to determine the independent predictors of ARDS, DIC,
SCAP, and 28-day mortality. All statistical tests were two-
tailed, and P < 0.05 was considered statistically signifi-
cant. Spearman correlation analysis was applied to deter-
mine the correlation between Presepsin, PCT, leukocyte,
lactate, and CURB65 score.
Results
Characteristics of enrolled subjects
Between November 2011 and October 2012, 573 patients
were enrolled after excluding 57 patients with missing clin-
ical data andwhowere finally diagnosedwith a disease other
than CAP, 36 patients lost to follow-up, and 25 patients who
did not consent to participate in the study. The enrolled
patientswere followed for 28 days or until death. Therewere
no significant differences between CAPand SCAP groupswith
respect to sex and co-morbidities. The characteristics,
coexisting illness, hospital admission, and associated labo-
ratory findings of enrolled subjects are listed in Table 1.
Comparison of Presepsin levels between patients
with CAP and SCAP, survivors and non-survivors at
the 28-day follow-up
The median Presepsin level, PCT level, leukocyte count, and
lactate level in each group are shown in Table 1. Plasma Pre-
sepsin levels at ED admission were significantly higher in pa-
tients with SCAP than in patients with CAP (689.0
[395.5e1225.5] pg/mL vs 400.0 [231.5e691.5] pg/mL,
P < 0.0001), and in non-survivors than survivors at the 28-day
follow-up (699.0 [373.0e1250.0] pg/mL vs 410.5
[242.3e697.0] pg/mL, P < 0.0001). Plasma Presepsin levels
weremarkedly higher in non-survivors than in survivors in each
group (CAP group, 588.0 [333.0e891.0] pg/mL vs 361.0
[218.0e589.0] pg/mL, P < 0.0001; SCAP group, 781.0
[437.0e1427.0] pg/mL vs 520.0 [352.0e1014.5.0] pg/mL,
PZ 0.004) (Fig. 1).
Comparison of plasma Presepsin levels on the basis
of CURB65 score
CAP patients were divided into groups according to three
CURB65 score risk categories: low (0e1), moderate (2), andhigh (3) risk, Median Presepsin levels were 353.0
[196.0e685.0] pg/mL, 385.0 [230.8e613.5] pg/mL, and
588.0 [362.0e1020.0] pg/mL, respectively, in each group.
Median Presepsin levels were significantly higher in CAP
patients with CURB65 (3) than CURB65 (0e1) or CURB65
(2) (all P < 0.0001). There was no significant differences
between CURB65 (0e1) and CURB65 (2) groups (P Z 0.317)
(Fig. 2).
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with and without ARDS, with and without DIC, and
in survivors and non-survivors with ARDS or DIC at
the 28-day follow-up
Plasma Presepsin levels at ED admission were significantly
higher (P < 0.0001) in patients with ARDS than without
ARDS (777.0 [423.8e1307.0] pg/mL vs 416.0
[253.0e753.3] pg/mL), and in patients with DIC than
without DIC (723.0 [441.0e1542.5] pg/mL vs 427.0
[266.5e779.5] pg/mL). Plasma Presepsin levels were
significantly higher in non-survivors compared with survi-
vors at 28-day follow-up in CAP patients with ARDS (844.5
[499.5e1409.3] pg/mL vs 506.0 [355.0e1020.0] pg/mL,
P Z 0.024) or DIC (833.0 [623.0e2145.3] pg/mL vs 503.0
[230.5e1097.5] pg/mL, P Z 0.001) (Fig. 3).Performance of various parameters for predicting
ARDS, DIC, SCAP, and 28-day mortality
The AUCs of Presepsin, PCT, leukocyte, lactate, and CURB65
score for predicting ARDS, DIC, SCAP, and 28-daymortality in
CAP patients are demonstrated in Table 2. AUCs of PresepsinFigure 3 Plasma Presepsin levels in patients with ARDS and non-
the 28-day follow-up with ARDS or DIC. Lines denote median values,
range.for predicting ARDS, DIC, SCAP, and 28-day mortality were
0.684, 0.658, 0.679, and 0.672, respectively; AUCs of CURB65
were 0.824, 0.570, 0.903, and 0.703, respectively; AUCs of
Presepsin in combination with CURB65 were 0.847, 0.916,
and 0.731 for predicting ARDS, SCAP, and 28-day mortality,
respectively, and these AUCs were greater than those of
Presepsin alone or CURB65 score alone (all P < 0.01). The
AUCs of Presepsin were significantly higher than those of
leukocyte count or CURB65 score for predicting DIC (all
P < 0.01), and there were no significant differences
compared with PCT and lactate (all P > 0.05). The detailed
results are presented in Table 2. The optimal cutoff value,
sensitivity, specificity, PPV, NPV, LRþ, and LR on the basis
of the ROC curves are presented in Table 3.
Independent predictors of ARDS, DIC, SCAP, and 28-
day mortality
Sex, age, Presepsin level, PCT level, leukocyte count, lactate
level, and CURB65 score were included in a binary logistic
regressionmodel to determine the independent predictors of
ARDS, DIC, SCAP, and 28-day mortality. CURB65, lactate
level, and age were found to be independent predictors of
ARDS. Presepsin level, lactate level, and age wereARDS, and with and without DIC, survivors and non-survivors at
boxes represent 25e75th percentiles and whiskers indicate the
Table 2 AUCs of various parameters for predicting ARDS, DIC, SCAP and 28-day mortality.
Variable AUC SE P-value 95% CI
Lower limit Upper limit
ARDS Presepsin 0.684 0.026 0 0.632 0.735
PCT 0.699 0.025 0 0.649 0.748
Leukocyte 0.531 0.031 0.292 0.470 0.592
Lactate 0.714 0.027 0 0.660 0.768
CURB65 0.824 0.019 0 0.787 0.862
Presepsin þ CURB65 0.847* 0.017 0 0.813 0.881
DIC Presepsin 0.658# 0.033 0 0.593 0.724
PCT 0.645 0.034 0 0.579 0.710
Leukocyte 0.488 0.037 0.711 0.415 0.560
Lactate 0.669 0.034 0 0.603 0.735
CURB65 0.570 0.033 0.036 0.505 0.634
Presepsin þ CURB65 0.648※ 0.034 0 0.581 0.715
SCAP Presepsin 0.679 0.023 0 0.634 0.724
PCT 0.665 0.023 0 0.619 0.710
Leukocyte 0.575 0.026 0.003 0.525 0.625
Lactate 0.695 0.024 0 0.649 0.741
CURB65 0.903 0.013 0 0.877 0.928
Presepsin þ CURB65 0.916* 0.012 0 0.894 0.939
28-day mortality Presepsin 0.672 0.024 0 0.026 0.719
PCT 0.683 0.023 0 0.637 0.729
Leukocyte 0.581 0.026 0.001 0.530 0.632
Lactate 0.703 0.023 0 0.657 0.748
CURB65 0.703 0.022 0 0.659 0.747
Presepsin þ CURB65 0.735* 0.021 0 0.689 0.773
*compared with Presepsin or CURB65, all P < 0.01; #compared with Leukocyte or CURB65, all P < 0.01; ※compared with CURB65,
P < 0.01; AUC: areas under the receiver operating curve; SE: Standard Error; CI: Confidence Interval. PCT: procalcitonin; CURB65:
confusion, urea >7 mmol/L, respitatory rate 30 breaths per minute, systolic pressure <90 mm Hg or diastolic pressure 60 mm Hg, and
age 65 years.
Table 3 Performance characteristics of multivariable in predicting ARDS, DIC, SCAP and 28-day mortality.
Variable Cutoff values Sensitivity Specificity PPV NPV LRþ LR-
ARDS Presepsin 468.5 pg/mL 72.6% 57.8% 32.4% 88.4% 1.72 0.47
PCT 1.21 ng/mL 60.8% 70.8% 36.7% 86.6% 2.08 0.55
Leukocyte 12.515  109/L 52.0% 58.9% 26.1% 81.5% 1.27 0.81
Lactate 2.55 mmol/L 67.2% 71.7% 39.8% 88.7% 2.37 0.46
CURB65 3.5 scores 65.6% 84.8% 54.7% 89.8% 4.32 0.41
DIC Presepsin 591.5 pg/mL 64.0% 65.5% 25.6% 90.8% 1.86 0.55
PCT 1.285 ng/mL 57.3% 69.0% 25.4% 89.8% 1.85 0.62
Leukocyte 22.61  109/L 13.5% 93.6% 27.9% 85.5% 2.11 0.92
Lactate 2.85 mmol/L 59.6% 73.1% 29.0% 90.8% 2.22 0.55
CURB65 3.5 scores 33.7% 75.2% 20.0% 86.1% 1.36 0.88
SCAP Presepsin 498.5 pg/mL 63.4% 64.4% 51.5% 74.7% 1.78 0.57
PCT 1.125 ng/mL 53.7% 72.7% 54.0% 72.5% 1.97 0.64
Leukocyte 12.515  109/L 53.3% 62.4% 45.8% 69.1% 1.42 0.75
Lactate 2.65 mmol/L 56.1% 78.3% 60.6% 74.9% 2.59 0.56
CURB65 3.5 scores 65.0% 96.9% 92.7% 82.3% 20.97 0.04
28-day mortality Presepsin 556.0 pg/mL 60.2% 68.4% 50.0% 76.6% 1.91 0.58
PCT 0.955 ng/mL 58.7% 71.1% 51.3% 76.8% 2.03 0.58
Leukocyte 14.17  109/L 43.9% 71.6% 44.6% 71.1% 1.55 0.78
Lactate 2.45 mmol/L 76.0% 66.3% 54.0% 84.2% 2.26 0.36
CURB65 2.5 scores 77.6% 57.3% 48.6% 83.1% 1.82 0.39
PPV: positive predictive value; NPV: negative predictive value; LRþ: positive likelihood ratio, LR-: negative likelihood ratio. PCT:
procalcitonin; CURB65: confusion, urea >7 mmol/L, respiratory rate 30 breaths per minute, systolic pressure <90 mm Hg or diastolic
pressure 60 mm Hg, and age 65 years.
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Table 4 Independent factors predicting ARDS, DIC, SCAP and 28-day mortality.
Variable B SE Wald df P-value OR 95% CI
Lower limit Upper limit
ARDS Presepsin 0 0 0.140 1 0.708 1.000 1.000 1.000
PCT 0.003 0.004 0.683 1 0.409 1.003 0.995 1.012
Leukocyte 0.018 0.014 1.691 1 0.193 0.982 0.955 1.009
Lactate 0.115 0.035 10.719 1 0.001 1.122 1.047 1.202
CURB65 1.136 0.142 84.049 1 0.000 3.691 2.792 4.879
Sex 0.169 0.252 0.449 1 0.503 0.503 0.723 1.939
Age 0.026 0.011 5.607 1 0.018 0.018 0.954 0.996
Constant 3.850 0.817 22.188 1 0 0.021
DIC Presepsin 0 0 11.894 1 0.001 1.000 1.000 1.001
PCT 0.006 0.004 3.098 1 0.078 1.006 0.999 1.014
Leukocyte 0.005 0.008 0.311 1 0.577 1.005 0.989 1.021
Lactate 0.087 0.032 7.324 1 0.007 1.091 1.024 1.162
CURB65 0.196 0.117 2.819 1 0.093 1.217 0.968 1.531
Sex 0.151 0.258 0.344 1 0.557 1.163 0.702 1.928
Age 0.025 0.009 6.756 1 0.009 0.976 0.958 0.994
Constant 1.517 0.618 6.020 1 0.014 0.219
SCAP Presepsin 0 0 0.255 1 0.614 1.000 1.000 1.000
PCT 0.009 0.005 3.235 1 0.072 1.009 0.999 1.020
Leukocyte 0.001 0.015 0.006 1 0.936 0.999 0.970 1.028
Lactate 0.204 0.048 18.125 1 0.000 1.226 1.116 1.346
CURB65 2.421 0.220 121.098 1 0.000 11.255 7.313 17.322
Sex 0.540 0.281 3.690 1 0.055 1.715 0.989 2.975
Age 0.025 0.013 3.667 1 0.056 0.976 0.951 1.001
Constant 7.015 1.048 44.810 1 0 0.001
28-day mortality Presepsin 0 0 7.602 1 0.006 1.000 1.000 1.001
PCT 0.007 0.004 3.345 1 0.067 1.007 0.999 1.015
Leukocyte 0.022 0.014 2.583 1 0.108 1.022 0.995 1.049
Lactate 0.056 0.031 3.348 1 0.067 1.058 0.996 1.123
CURB65 0.531 0.097 30.147 1 0.000 1.701 1.407 2.056
Sex 0.154 0.199 0.603 1 0.437 0.857 0.580 1.265
Age 0 0.008 0 1 0.988 1.000 0.984 1.017
Constant 2.851 0.612 21.719 1 0 0.058
SE: Standard Error; OR: Odds ratio; CI: Confidence Interval. PCT: procalcitonin; CURB65: confusion, urea>7 mmol/L, respiratory rate
30 breaths per minute, systolic pressure <90 mm Hg or diastolic pressure 60 mm Hg, and age 65 years.
1210 B. Liu et al.independent predictors of DIC. CURB65 and lactate level
were independent predictors of SCAP. Presepsin and CURB65
were independent predictors of 28-day mortality. The
detailed results are presented in Table 4.
Correlation of Presepsin with PCT, leukocyte,
lactate, and CURB65 score
A Spearman analysis of the correlation of Presepsin level
with PCT level, leukocyte count, lactate level, and CURB65
score found that the correlation coefficients of Presepsin
were 0.444, 0.163, 0.339, and 0.301, respectively (all
P < 0.01), which suggested significant positive correlations.
Comparison of survival rate in patients above or
below the Presepsin cutoff for predicting 28-day
mortality in CAP patients
To demonstrate the capacity of Presepsin for risk stratifi-
cation in CAP patients, a comparison of survival using
KaplaneMeier survival curves was performed. CAP patientswith plasma Presepsin levels above the cutoff (556.0 pg/
mL) had significantly lower survival rates compared with
patients with levels below this cutoff (50.0% vs 76.6%;
P < 0.0001) (Fig. 4).
Discussion
This study demonstrated that plasma Presepsin levels were
markedly different in CAP and SCAP patients, and were
significantly higher in SCAP patients than in CAP patients at
ED admission. In addition, plasma Presepsin levels increased
with an increase in CURB65 score, and reached the highest
levels in CAP patients with a CURB65 score 3. Additionally,
in CAP and SCAP patients, there were significantly higher
plasma Presepsin levels in non-survivors than in survivors.
The present study suggested that the contribution of plasma
Presepsin levels to the evaluation of CAP patients varied
according to severity of CAP, and was a good parameter for
reflecting the severity and prognosis of CAP patients.
Taking into account the importance of CAP in terms of
morbidity and mortality, early identification of patients at
Figure 4 KaplaneMeier curves for Presepsin in CAP patients
at the 28-day follow-up. Solid lines represent non-survivors,
and dashed lines represent survivors.
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our knowledge, this is the first study to assess the useful-
ness of plasma Presepsin levels for CAP complications. The
ARDS, the more severe form of acute lung injury (ALI), is
one of the most serious complications of CAP. In the United
States, ALI and ARDS affect 150,000e200,000 patients per
year, resulting in a burden of 3.6 million hospital days per
year and a mortality rate of 30e40% [17,18]. Furthermore,
early prediction and timely intervention for ARDS are
crucial for improving prognosis in CAP patients. Previous
studies on biomarkers have demonstrated that specific
biomarkers were associated with increased disease severity
and poorer clinical outcomes in patients with ALI/ARDS
[19,20]. sCD14, a new infection-related biomarker, is pre-
sent in the circulation and other body fluids, and levels of
sCD14 in plasma increase during inflammation and infection
[21]. Martin et al. [22] found that sCD14 levels were
markedly increased in bronchoalveolar lavage (BAL) fluid
from patients with ARDS, and concluded that sCD14
contributed to the inflammatory process in the lung. In the
present study, we found that plasma Presepsin (sCD14-ST)
levels were significantly higher in CAP patients with ARDS
than in those without ARDS, which was in line with the
previous study of BAL fluid in ARDS patients. Additionally,
we also found that there were significantly higher plasma
Presepsin levels in non-survivors than in survivors with
ARDS. Taken together, the plasma Presepsin level was
closely associated with the incidence of ARDS in CAP pa-
tients, and was a good parameter to reflect 28-day mor-
tality in these patients.
Coagulation abnormalities are frequent in patients
with severe infections. DIC is characterized by wide-
spread activated coagulation and suppression of fibrino-
lysis, resulting in intravascular fibrin formation and
thrombotic occlusion of microvessels [23e26]. It is now
accepted that DIC can originate from and cause damage
to the microvasculature, which can produce organdysfunction if sufficiently severe, and that DIC reflects an
inflammatory disorder of the microvasculature [24].
Therefore, earlier diagnosis and treatment of DIC would
contribute to a better outcome in patients with this dis-
order [27]. Similarly, the present study also indicated that
plasma Presepsin levels were significantly higher in DIC
patients than in non-DIC patients, and there were signif-
icantly higher plasma Presepsin levels in non-survivors
compared with survivors, suggesting plasma Presepsin
levels were a better predictor of DIC in CAP patients, and
higher plasma Presepsin levels indicated an adverse
medical outcome.
Previous studies have proposed that ALI and ARDS are
closely linked to systemic activation of inflammation and
coagulation, and that simultaneous activation of inflam-
mation and coagulation occur in the early stage of ALI and
ARDS [28,29]. In our study, ARDS or DIC was confirmed at ED
admission, and plasma Presepsin levels were elevated in
ARDS and DIC patients at the same time, thus plasma Pre-
sepsin levels reflected the early pathophysiological condi-
tion of ARDS and DIC patients.
Accurate, objective models of prognosis for CAP could
help physicians assess patient risk and improve the de-
cisions about hospitalization [2]. Recent interest has
focused on scoring systems in combination with biomarkers
for assessment of severity and evaluation of prognosis of
CAP patients. The CURB65 scoring system, a simplified
assessment tool developed by the British Thoracic Society,
focuses on only five predictors, and is easier to remember
and apply [4,30]. To improve the predictive accuracy of
clinical severity scores, some biomarkers have been pro-
posed to provide more detailed and complementary infor-
mation. Previous studies have confirmed that precursor
levels of adrenomedullin, endothelin-1, atrial natriuretic
peptide, antidiuretic hormone, and PCT levels on admission
and during follow-up showed high prognostic accuracy for
mortality and serious complications in CAP patients [31],
but to date, Presepsin has not been investigated as a factor
for prediction of adverse medical events and complica
tions.
The current study had several strengths. First, the
CURB65 score had high specificity (84.8%) and NPV
(89.8%), and was an independent predictor of ARDS.
Although Presepsin was not an independent predictor of
ARDS, the Presepsin level significantly increased the AUC
of the CURB65 score for predicting ARDS. Presepsin had a
high NPV (88.4%), and simultaneously displayed a positive
correlation with CURB65 score. Thus, the CURB65 score in
combination with Presepsin significantly improved the
accuracy of predicting ARDS, and lower than the cutoffs
of 468.5 pg/mL for Presepsin and 3.5 scores for CURB65
may help rule out the possibility of ARDS. Similarly, the
CURB65 score demonstrated high specificity (96.9%) and
PPV (92.7%) for predicting SCAP. Presepsin also signifi-
cantly increased with CURB65 score, and enhanced the
accuracy of the CURB65 score in predicting SCAP, and
higher than the cutoffs of 498.5 pg/mL for Presepsin and
3.5 scores for CURB65 may help predict the possibility of
SCAP. Second, in this study, we also found that Presepsin
had a high NPV (90.8%) and was an independent predictor
of DIC, but Presepsin in conjunction with CURB65 score
did not increase the AUC. This indicated that Presepsin
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591.5 pg/mL possibly ruling out the possibility of DIC.
Third, we further found that although the AUCs of Pre-
sepsin and CURB65 score were a little low for predicting
28-day mortality (0.672 and 0.703, respectively), Pre-
sepsin in conjunction with CURB65 score markedly
increased the AUC (0.735). In addition, multivariable
regression analysis found that both were independent
predictors of 28-day mortality, and Presepsin in conjunc-
tion with CURB65 score significantly elevated the predic-
tive accuracy. KaplaneMeier survival curves
demonstrated that CAP patients with plasma Presepsin
levels above a cutoff of 556.0 pg/mL had significantly
lower survival rates compared with patients with levels
below this cutoff. Thus, lower than the cutoffs of
556.0 pg/mL for Presepsin and 2.5 scores for CURB65 may
exclude the possibility of death. Fourth, we found that
although AUCs of lactate for predicting ARDS, DIC, SCAP,
and 28-day mortality in CAP patients were slightly higher
than that of Presepsin, there were no significant differ-
ences. Additionally, our present study found that blood
lactate was also a better predictor of mortality in CAP
patients, which was in line with previous studies [32e34].
Presepsin levels were positively correlated with lactate
levels, further validating Presepsin as a biomarker
reflecting prognosis in CAP patients.
Limitations
There were some limitations in our study. First, our study
was a single-center study, so the results may not be
applicable to other EDs. Second, CAP patients were
mainly enrolled from the critical care unit of the ED, and
suffered from multiple chronic diseases, so had high
mortality (CAP group 22%, SCAP group 54.7%), and hence
may not represent the overall population of CAP patients.
Third, only plasma Presepsin levels at ED enrollment were
measured, and the dynamic changes of Presepsin were
unknown. Fourth, it was difficult to obtain pathogen
samples in an ED setting, so there was a lack of etiological
evidence of CAP. For this reason, a multicenter clinical
study including etiology will be needed to further inves-
tigate the serial changes in Presepsin levels in CAP
patients.
Conclusion
The present study suggests that Presepsin is a promising
biomarker for reflecting the severity of CAP. Presepsin has
predictive value for predicting ARDS, DIC, SCAP, and 28-day
mortality, and is an independent predictor of DIC and 28-
day mortality in CAP patients. Presepsin in combination
with CURB65 score may improve the predictive accuracy for
ARDS, SCAP, and 28-day mortality. Presepsin is a valuable
biomarker in predicting severity and outcome in CAP pa-
tients in the ED.
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